Kiromic BioPharma, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Pietro Bersani CPA,
- Full Time Employees
- 44
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 7707 Fannin Houston TX United States of America 77054
- IPO Date
- Oct 16, 2020
- CIK
- 0001792581
- Website
- kiromic.com
- Similar Companies
- Business
- Kiromic BioPharma, Inc. (KRBP) is a clinical-stage biotherapeutics company that develops cell therapies targeting solid tumors using non-engineered and engineered allogeneic Gamma Delta T (GDT) cell technologies and its proprietary DIAMOND AI target discovery platform; core product candidates include Deltacel (KB-GDT-01), in Phase 1 trials for non-small cell lung cancer in combination with low-dose radiation, Procel, and Isocel, each addressing unmet needs in immuno-oncology for solid tumors representing 90% of cancers. The company, founded in 2006 and headquartered in Houston, Texas, focuses on the United States market with investigational new drug applications planned for additional GDT-based trials. In March 2025, Kiromic filed for Chapter 7 bankruptcy protection, leading to an asset purchase agreement in April 2025 with Immunocell Therapeutics Inc., one of its investors, to acquire key assets including ongoing clinical trials such as the recruiting Deltacel Phase 1 study with 48 estimated participants set for completion in 2026; this expedited sale aims to minimize disruption to operations and preclinical programs amid prior pipeline prioritization of off-the-shelf allogeneic therapies announced in 2022.
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
Kiromic BioPharma Reports Tumor Volume Decrease in Two Patients Enrolled in Deltacel-01
Kiromic BioPharma Announces Settlement of Previously Disclosed SEC Investigation
SEC Charges Kiromic BioPharma and Two Former C-Suite Executives with Misleading Investors about Status of FDA Reviews
Kiromic BioPharma Reports Favorable Ongoing Clinical Results From Fourth and Sixth Patients Enrolled in Deltacel-01
Kiromic BioPharma Activates the University of Arizona Cancer Center as the Fifth Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Kiromic BioPharma Provides Update on Part 1 of the Deltacel-01 Trial
Kiromic BioPharma Provides Updates on its Deltacel-01 Clinical Trial
Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
Kiromic BioPharma Reports Favorable Results at Six Weeks from Fourth Patient in Deltacel-01 Clinical Trial
Kiromic BioPharma Adds UPMC as Fourth Deltacel-01 Clinical Trial Site
Kiromic BioPharma Reports Consistent Favorable Safety, Tolerability, and Efficacy in Deltacel-01 Clinical Trial First Three Patients
Kiromic BioPharma Reports Favorable Safety, Tolerability, and Early Efficacy from Third Patient in Deltacel-01 Clinical Trial
Early Efficacy Results Show Primary Lung Tumor Stabilization and Complete Disappearance of Brain Metastases in Second Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial
Kiromic BioPharma Adds Virginia Oncology Associates, PC as the Second Clinical Trial Site in the Ongoing Phase 1 Deltacel-01 Trial
Kiromic BioPharma to Present at the OTC Markets' Virtual Life Science Investor Forum on March 7th
Results from First Patient in Kiromic BioPharma's Deltacel-01 Clinical Trial Indicate Tumor Reduction at Two Months
Kiromic BioPharma Reports Favorable Early Efficacy Results from First Patient in Deltacel-01 Phase 1 Clinical Trial in Non-Small Cell Lung Cancer
Kiromic BioPharma Reports Favorable Early Safety and Tolerability Data from First Patient Enrolled in the Phase 1 Deltacel-01 Clinical Trial
Kiromic BioPharma Announces First Patient Dosed in Phase 1 Study Evaluating Deltacel™ for the Treatment of Non-Small Cell Lung Cancer